Critics slate ethical leeway in California stem-cell proposal
By Jonathan Knight,
Nature
| 09. 16. 2004
Opponents of California's $3-billion plan to fund embryonic
stem-cell research say that the proposal would give researchers carte
blanche to rewrite well-established ethical guidelines to suit their
needs.
They say the research institute planned
under the initiative will be exempt from legislative supervision and,
if established, will be able to make its own rules about conflicts of
interest and informed consent.
Proponents are
reacting angrily to the charges, saying that the proposal provides the
highest possible level of accountability and will serve as a model of
how science can be funded at the state level.
The
California Stem Cell Research and Cures Initiative will appear as
Proposition 71 on the ballot in the elections due on 2 November. If
passed, it will authorize a bond issue of nearly $3 billion over ten
years to fund embryonic stem-cell research and infrastructure. It will
create the California Institute for Regenerative Medicine to distribute
the funds.
But public opinion is sharply divided on
the proposition, with 45% in favour and 42% opposed. A California
columnist has branded it an "audacious raid on the...
Related Articles
By David Jensen, California Stem Cell Report | 02.10.2026
Touchy issues involving accusations that California’s $12 billion gene and stem cell research agency is pushing aside “good science” in favor of new priorities and preferences will be aired again in late March at a public meeting in Sacramento.
The...
By Roni Caryn Rabin, The New York Times | 01.22.2026
The National Institutes of Health said on Thursday it is ending support for all research that makes use of human fetal tissue, eliminating funding for projects both within and outside of the agency.
A ban instituted in June 2019 by...
By David Jensen, The California Stem Cell Report | 12.11.2025
California’s stem cell and gene therapy agency today approved spending $207 million more on training and education, sidestepping the possibility of using the cash to directly support revolutionary research that has been slashed and endangered by the Trump administration.
Directors...
By Frankie Fattorini, Pharmaceutical Technology | 12.02.2025
Próspera, a charter city on Roatán island in Honduras, hosts two biotechs working to combat ageing through gene therapy, as the organisation behind the city advertises its “flexible” regulatory jurisdiction to attract more developers.
In 2021, Minicircle set up a...